Plain-English translation of NCT06339775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a treatment combination for people with acute B-cell leukemia who have relapsed (their cancer has returned) after receiving a stem cell transplant. The doctors will give patients a medication called followed by an infusion of immune cells from the original donor. The goal is to see if this combination can help fight the cancer and improve survival.
When leukemia comes back after a stem cell transplant, treatment options are limited and the outlook can be serious. This trial is exploring whether this medication combined with donor immune cells—which can recognize and attack leukemia cells—might offer a better chance of remission and long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive as an infusion, with the dose and duration tailored based on whether your leukemia is in an early stage (detected by blood tests) or has fully returned. About 1–2 months after this medication, you will receive an infusion of donor immune cells. You will be closely monitored through regular follow-up visits to track how well the treatment is working, watch for side effects, and measure how long you survive without your cancer returning.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China